Editas Medicine Inc (NASDAQ: EDIT) kicked off on Tuesday, up 0.71% from the previous trading day, before settling in for the closing price of $1.41. Over the past 52 weeks, EDIT has traded in a range of $1.12-$11.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 135.89% over the last five years. While this was happening, its average annual earnings per share was recorded -33.69%. With a float of $81.78 million, this company’s outstanding shares have now reached $82.54 million.
The firm has a total of 265 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.46%, operating margin of -370.03%, and the pretax margin is -340.96%.
Editas Medicine Inc (EDIT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 67.71%. The most recent insider transaction that took place on Dec 03 ’24, was worth 3,361. In this transaction CEO of this company sold 1,618 shares at a rate of $2.08, taking the stock ownership to the 312,106 shares. Before that another transaction happened on Dec 03 ’24, when Company’s EVP, CHIEF MEDICAL OFFICER sold 541 for $2.08, making the entire transaction worth $1,124. This insider now owns 133,354 shares in total.
Editas Medicine Inc (EDIT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -33.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.23% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Take a look at Editas Medicine Inc’s (EDIT) current performance indicators. Last quarter, stock had a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Analysing the last 5-days average volume posted by the [Editas Medicine Inc, EDIT], we can find that recorded value of 2.9 million was better than the volume posted last year of 2.67 million. As of the previous 9 days, the stock’s Stochastic %D was 78.20%. Additionally, its Average True Range was 0.14.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 10.00%, which indicates a significant decrease from 66.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.08% in the past 14 days, which was lower than the 83.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7230, while its 200-day Moving Average is $3.8222. Now, the first resistance to watch is $1.4733. This is followed by the second major resistance level at $1.5267. The third major resistance level sits at $1.6033. If the price goes on to break the first support level at $1.3433, it is likely to go to the next support level at $1.2667. Now, if the price goes above the second support level, the third support stands at $1.2133.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
The company with the Market Capitalisation of 117.22 million has total of 82,548K Shares Outstanding. Its annual sales at the moment are 78,120 K in contrast with the sum of -153,220 K annual income. Company’s last quarter sales were recorded 60 K and last quarter income was -62,140 K.
